Eliem Therapeutics (ELYM) Competitors $1.21 +0.01 (+0.83%) As of 04/2/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ELYM vs. IVA, HURA, GLSI, LRMR, CGEN, ZNTL, ACTU, OGI, SAVA, and DERMShould you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include Inventiva (IVA), TuHURA Biosciences (HURA), Greenwich LifeSciences (GLSI), Larimar Therapeutics (LRMR), Compugen (CGEN), Zentalis Pharmaceuticals (ZNTL), Actuate Therapeutics (ACTU), Organigram (OGI), Cassava Sciences (SAVA), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry. Eliem Therapeutics vs. Inventiva TuHURA Biosciences Greenwich LifeSciences Larimar Therapeutics Compugen Zentalis Pharmaceuticals Actuate Therapeutics Organigram Cassava Sciences Journey Medical Inventiva (NASDAQ:IVA) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership. Which has more risk and volatility, IVA or ELYM? Inventiva has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.39, suggesting that its stock price is 139% less volatile than the S&P 500. Does the MarketBeat Community favor IVA or ELYM? Inventiva received 14 more outperform votes than Eliem Therapeutics when rated by MarketBeat users. Likewise, 82.14% of users gave Inventiva an outperform vote while only 56.25% of users gave Eliem Therapeutics an outperform vote. CompanyUnderperformOutperformInventivaOutperform Votes2382.14% Underperform Votes517.86%Eliem TherapeuticsOutperform Votes956.25% Underperform Votes743.75% Does the media favor IVA or ELYM? In the previous week, Inventiva had 5 more articles in the media than Eliem Therapeutics. MarketBeat recorded 5 mentions for Inventiva and 0 mentions for Eliem Therapeutics. Inventiva's average media sentiment score of 0.10 beat Eliem Therapeutics' score of 0.00 indicating that Inventiva is being referred to more favorably in the media. Company Overall Sentiment Inventiva Neutral Eliem Therapeutics Neutral Is IVA or ELYM more profitable? Inventiva's return on equity of 0.00% beat Eliem Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets InventivaN/A N/A N/A Eliem Therapeutics N/A -47.03%-45.97% Do institutionals & insiders hold more shares of IVA or ELYM? 19.1% of Inventiva shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 32.0% of Inventiva shares are held by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer IVA or ELYM? Inventiva currently has a consensus price target of $12.60, suggesting a potential upside of 309.76%. Given Inventiva's stronger consensus rating and higher probable upside, analysts plainly believe Inventiva is more favorable than Eliem Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inventiva 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings & valuation, IVA or ELYM? Eliem Therapeutics has lower revenue, but higher earnings than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInventiva$15.62M10.33-$119.51MN/AN/AEliem TherapeuticsN/AN/A-$35.12M-$0.53-2.28 SummaryInventiva beats Eliem Therapeutics on 12 of the 14 factors compared between the two stocks. Remove Ads Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELYM vs. The Competition Export to ExcelMetricEliem TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36M$6.56B$5.40B$7.28BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-2.286.8522.8817.61Price / SalesN/A194.91357.3086.64Price / CashN/A65.6738.1634.64Price / Book0.315.746.323.86Net Income-$35.12M$142.37M$3.21B$247.18M7 Day Performance-4.72%-9.71%-6.89%-6.27%1 Month Performance-16.55%-12.66%-1.87%-8.87%1 Year Performance-56.63%-16.65%4.62%-6.18% Eliem Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELYMEliem TherapeuticsN/A$1.21+0.8%N/A-57.7%$36MN/A-2.289IVAInventiva1.9322 of 5 stars$2.92+3.5%$12.60+331.5%-17.3%$153.23M$15.62M0.00100HURATuHURA BiosciencesN/A$3.59+7.8%$13.00+262.1%N/A$151.80MN/A0.00N/AAnalyst ForecastAnalyst RevisionHigh Trading VolumeGLSIGreenwich LifeSciences1.6496 of 5 stars$11.25+1.3%$38.00+237.8%-47.8%$147.88MN/A-14.063News CoverageGap DownLRMRLarimar Therapeutics2.5168 of 5 stars$2.28-10.2%$20.13+782.7%-74.4%$145.48MN/A-1.9830Gap DownHigh Trading VolumeCGENCompugen1.2449 of 5 stars$1.62+3.2%$4.00+146.9%-42.0%$144.56M$27.86M81.0070Gap DownZNTLZentalis Pharmaceuticals1.6051 of 5 stars$1.98+3.7%$8.24+316.4%-91.8%$141.11M$40.56M-0.80160Gap DownACTUActuate TherapeuticsN/A$7.20+6.7%$20.00+177.8%N/A$140.63MN/A0.0010Gap DownOGIOrganigram0.5444 of 5 stars$1.11flatN/A-57.2%$140.10M$166.12M-2.92860SAVACassava Sciences3.848 of 5 stars$2.80-1.4%$111.50+3,882.1%-93.8%$137.20MN/A-2.0330Short Interest ↓Gap DownDERMJourney Medical2.3592 of 5 stars$6.54+13.9%$9.67+47.8%+92.7%$136.62M$57.77M-6.9690High Trading Volume Remove Ads Related Companies and Tools Related Companies Inventiva Alternatives TuHURA Biosciences Alternatives Greenwich LifeSciences Alternatives Larimar Therapeutics Alternatives Compugen Alternatives Zentalis Pharmaceuticals Alternatives Actuate Therapeutics Alternatives Organigram Alternatives Cassava Sciences Alternatives Journey Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELYM) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ELYM Stock Free ELYM Stock Alerts